384 related articles for article (PubMed ID: 12839949)
1. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
Theti DS; Bavetsias V; Skelton LA; Titley J; Gibbs D; Jansen G; Jackman AL
Cancer Res; 2003 Jul; 63(13):3612-8. PubMed ID: 12839949
[TBL] [Abstract][Full Text] [Related]
2. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Theti DS; Jackman AL
Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
[TBL] [Abstract][Full Text] [Related]
3. Targeting the alpha-folate receptor with cyclopenta[g]quinazoline-based inhibitors of thymidylate synthase.
Henderson EA; Bavetsias V; Theti DS; Wilson SC; Clauss R; Jackman AL
Bioorg Med Chem; 2006 Jul; 14(14):5020-42. PubMed ID: 16554160
[TBL] [Abstract][Full Text] [Related]
4. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Gibbs DD; Theti DS; Wood N; Green M; Raynaud F; Valenti M; Forster MD; Mitchell F; Bavetsias V; Henderson E; Jackman AL
Cancer Res; 2005 Dec; 65(24):11721-8. PubMed ID: 16357184
[TBL] [Abstract][Full Text] [Related]
5. Antifolates targeted specifically to the folate receptor.
Jackman AL; Theti DS; Gibbs DD
Adv Drug Deliv Rev; 2004 Apr; 56(8):1111-25. PubMed ID: 15094210
[TBL] [Abstract][Full Text] [Related]
6. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
8. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.
Drori S; Jansen G; Mauritz R; Peters GJ; Assaraf YG
J Biol Chem; 2000 Oct; 275(40):30855-63. PubMed ID: 10899164
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines.
Miotti S; Bagnoli M; Ottone F; Tomassetti A; Colnaghi MI; Canevari S
J Cell Biochem; 1997 Jun; 65(4):479-91. PubMed ID: 9178098
[TBL] [Abstract][Full Text] [Related]
10. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
11. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells.
Spinella MJ; Brigle KE; Sierra EE; Goldman ID
J Biol Chem; 1995 Apr; 270(14):7842-9. PubMed ID: 7713875
[TBL] [Abstract][Full Text] [Related]
14. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
15. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
16. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells.
Corona G; Giannini F; Fabris M; Toffoli G; Boiocchi M
Int J Cancer; 1998 Jan; 75(1):125-33. PubMed ID: 9426700
[TBL] [Abstract][Full Text] [Related]
17. Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.
Pillai RG; Forster M; Perumal M; Mitchell F; Leyton J; Aibgirhio FI; Golovko O; Jackman AL; Aboagye EO
Cancer Res; 2008 May; 68(10):3827-34. PubMed ID: 18483267
[TBL] [Abstract][Full Text] [Related]
18. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
19. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
[TBL] [Abstract][Full Text] [Related]
20. Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Erlichman C; Mitrovski B
Cancer Chemother Pharmacol; 1994; 34(1):51-6. PubMed ID: 8174202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
